Skip to main content

Table 3 Comparison of disease severity at baseline and at the end of the study period

From: A pseudo-randomised clinical trial of in situ gels of fluconazole for the treatment of oropharngeal candidiasis

Parameter

Group I

Group II

Group III

Group I

Group II

Group III

P Value

 

At day 0 (Baseline)

At day 44 (end of study period)

 

Extent of Lesion

1.03 ± 0.01

0.2 ± 0.02

1.13 ± 0.01

0.94 ± 0.02

0.01 ± 0.00

1.11 ± 0.01

0.36

Soreness/Burning

0.36 ± 0.05

0.13 ± 0.06

0.56 ± 0.05

0.46 ± 0.05

0.03 ± 0.00

0.66 ± 0.05

0.39

Erythema

0.93 ± 0.07

0.35 ± 0.01

1.03 ± 0.07

0.96 ± 0.05

0.00 ± 0.00

0.98 ± 0.07

0.42